News

WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year

SHANGHAI, October 29, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been awarded the 2024 Global CRDMO Company of the Year Award by Frost & Sullivan, a growth advisory firm. This marks the eighth consecutive year that WuXi AppTec has achieved this distinction.

Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY

(SHANGHAI, October 28, 2024) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the first three quarters ending September 30, 2024 (“Reporting Period”)

WuXi AppTec Maintains AA MSCI ESG Rating for the Fourth Consecutive Year

Shanghai, September 1, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently announced that it has maintained its AA MSCI (Morgan Stanley Capital International) ESG rating for the fourth consecutive year. The rating reflects WuXi AppTec’s commitment to incorporating environmental and social responsibilities into the company’s business strategies and operations.

Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ

- Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year - Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year - Net Profit Attributable to the Owners of the Company Reached RMB4,240 Million, and Diluted Earnings per Share (EPS) of RMB1.45 for the First Half - Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company Reached RMB4,372 Million, and Adjusted Non-IFRS Diluted EPS of RMB1.50 for the First Half - Excluding COVID-19 commercial projects, Operating Cash Flow Up 48.3%/RMB1.50 billion Year-over-Year for the First Half

WuXi AppTec Named to the FTSE4Good Index Series for the Second Consecutive Year

Shanghai, July 19, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced that it has been included in the FTSE4Good Index Series for the second consecutive year. This achievement recognizes WuXi AppTec's exceptional performance in environmental, social, and governance (ESG) practices driven by our commitment to advancing sustainability and enabling innovation for a healthier world.

Press Releases

WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year

Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY

WuXi AppTec Maintains AA MSCI ESG Rating for the Fourth Consecutive Year

Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ

WuXi AppTec Named to the FTSE4Good Index Series for the Second Consecutive Year